Primenenie antagonistov kal'tsiya v kardiologii
- Authors: Galyavich A.S1
-
Affiliations:
- Казанский государственный медицинский университет
- Issue: Vol 9, No 11 (2007)
- Pages: 49-52
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/92504
- ID: 92504
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##References
- Rohwedder D, Hacks M. Verapamil. A drug on the threshold of the next decade. Experts in dialoque. Hamburg, Zurich: Wissenschaftsverlag 1992: 9–18.
- Eisenberg M, Brox A, Bestawros A. Calcium Channel Blockers: An Update. Am J Med 2004; 116: 35–43.
- Elliot H.L, Meredith P.A, Reid J.L. Pharmacokinetics of Calcium Antagonists: Implications for Therapy. In: Calcium Antagonists in Clinical Medicine 2nd ed. Epstein M., Hanley&Belfus, 1998.
- Epstein M. Calcium Antagonists in the Man agement of Hypertension. In: Calcium Antago nists in Clinical Medicine 2nd ed. Epstein M., Hanley&Belfus, 1998.
- Toyooka T, Nayler W. Third generation calci um entry blockers. Blood pressure 1996; 5: 206–8.
- Guidelines for the Management of Arter ial Hypertension. J Hypertension 2007; 25: 1105–87.
- ВНОК. Диагностика и лечение стабиль ной стенокардии. Российские рекоменда ции. М., 2004.
- Poole-Wilson P.A, Lubsen J, Kirwan B.A et al. Effect of long - acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): ran domized controlled trial. Lancet 2004; 364: 849–57.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high - risk hypertensive patients ran domized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treat ment to Prevent Heart Attack (ALLHAT). JAMA 2002; 288: 2981–97.
Supplementary files
